Selank: Research Background and Overview

Selank is the sister compound to Semax — developed by the same Russian research group, built on the same design principle, but derived from an entirely different natural molecule and studied for a different set of questions. This overview covers what Selank is, where it came from, what the published literature has examined, and how researchers evaluate a reference sample. It is written for a research audience and makes no health, therapeutic, or performance claims.

What Selank is

Selank is a short synthetic peptide — a heptapeptide, seven amino acids in length. Its sequence is Thr-Lys-Pro-Arg-Pro-Gly-Pro.

The first four residues (Thr-Lys-Pro-Arg) are tuftsin, a naturally occurring tetrapeptide. Tuftsin is a fragment of the heavy chain of immunoglobulin G (IgG) and is best known in the immunology literature as a small immune-signaling molecule. On its own, tuftsin is broken down very quickly in the body.

As with Semax, Russian researchers attached a Pro-Gly-Pro tail to slow that degradation — the same stabilizing trick applied to a different parent molecule. That is the throughline of this research program: take a short natural peptide with an interesting signaling role, add a proline-rich tail so it survives long enough to study, and characterize what it does. Selank is therefore best described as a stabilized tuftsin analog.

Where it came from

Selank was developed at the Institute of Molecular Genetics of the Russian Academy of Sciences, the same institution — and the same design philosophy — behind Semax. The two are frequently discussed together for exactly this reason: sister compounds from one research program, one built on an ACTH fragment, the other on tuftsin.

Like Semax, Selank has been registered as a medicine in Russia, which is why much of the human-subject literature appears in Russian-language clinical journals. It has no U.S. or Western regulatory approval and has not been evaluated by the FDA or comparable agencies for any use. Western-accessible material is therefore largely preclinical or falls under laboratory research use — worth remembering when reading claims online.

What the published research has examined

Whereas Semax research centers on neurotrophic and melanocortin questions, the Selank literature clusters around two themes reflecting its tuftsin origin:

• Anxiolytic and GABAergic research. The most-cited line of Selank work investigates the peptide in animal models of anxiety-like behavior, and examines interactions with the GABA and serotonin systems and with the expression of related neuroregulatory genes. These are mechanistic and behavioral-model studies, not outcome trials.
• Immunomodulation. Because tuftsin is an immune-signaling fragment, a body of research has measured whether Selank exposure influences cytokine and interferon-related pathways — a natural question given the parent molecule's biology.
• BDNF and gene expression. As with Semax, researchers (notably the Institute's own groups) have profiled changes in brain-derived neurotrophic factor (BDNF) and in transcriptome-wide gene expression following Selank administration in rodent models — data-mapping work rather than efficacy claims.
• Peptide stability and binding. A separate strand of analytical work has characterized how the Pro-Gly-Pro tail affects Selank's degradation and how the peptide binds in tissue — the chemistry that made it studyable in the first place.

None of this establishes a benefit for any use in humans, and this article asserts none. The point is narrower: Selank is a genuine, peer-reviewed object of neuropeptide and immunopeptide research, and knowing what that research measures is what separates reading the science from reading the marketing.

Selank and Semax — the short version

They are often confused. They are not the same molecule:

• Different origin. Semax is built on a fragment of ACTH; Selank is built on tuftsin, an IgG fragment.
• Different research focus. The Semax literature leans neurotrophic/melanocortin; the Selank literature leans anxiolytic/immunomodulatory.
• Same lab, same design trick. Both are proline-tailed analogs from the Institute of Molecular Genetics, engineered for stability.

We're publishing a dedicated side-by-side comparison next; for now, the one-line distinction is ACTH-fragment vs. tuftsin-fragment, neurotrophic-focus vs. anxiolytic-focus.

Forms you'll encounter

In the research-materials market Selank is supplied as a research-use-only reference material — typically as either a lyophilized (freeze-dried) powder in a sealed vial — the most stable form, reconstituted with bacteriostatic water before use — or as a pre-mixed nasal solution, since intranasal delivery is the route most represented in the literature. A sealed lyophilized vial is inherently more shelf-stable than any pre-mixed liquid. Neither format implies an approved application; it simply reflects laboratory handling.

How a research sample's quality is evaluated

For any short synthetic peptide, "is it real and is it what the label says" is answered by analytical chemistry, not brand claims. Two documents matter:

1. A third-party Certificate of Analysis (COA) tied to the specific lot — it should reference the lot number printed on the vial in hand, not a generic batch.
2. HPLC purity data — high-performance liquid chromatography reports the target peptide as a percentage of the total, ideally a single clean dominant peak at high purity. A cluster of smaller peaks signals synthesis byproducts or degradation.

Our companion piece on how to read a Certificate of Analysis walks through what each figure on an HPLC report means.

Storage, in general terms

The same chemistry applies to every peptide: a sealed lyophilized vial kept cold and dark is far more forgiving than a reconstituted or pre-mixed solution, where hydrolysis proceeds much faster once the peptide is in water. Manufacturer and lot-specific guidance always supersedes general rules of thumb. We cover the underlying chemistry in how to store peptides.

Frequently asked questions

Is Selank approved by the FDA?
No. It has no U.S. or Western regulatory approval and has not been evaluated by those agencies. Its approvals are limited to Russia and a few neighboring countries.

What is tuftsin, and why does it matter here?
Tuftsin is a natural four-amino-acid fragment of the IgG antibody with a role in immune signaling. Selank is a stabilized analog of it — that origin is why part of the Selank literature examines immune-related pathways.

How is Selank different from Semax?
Same research program and same stabilizing design, but different parent molecules (tuftsin vs. an ACTH fragment) and different research focus (anxiolytic/immune vs. neurotrophic/melanocortin).

Why is so much of the research in Russian?
Because Selank was developed and registered as a medicine in Russia, most human-subject studies were published in Russian-language clinical journals; Western-accessible work is largely preclinical.

References

1. Ashmarin IP, et al. Design of stabilized regulatory peptides: tuftsin analogs. Institute of Molecular Genetics, Russian Academy of Sciences.
2. Zozulya AA, et al. "Efficacy and possible mechanisms of action of a new peptide anxiolytic Selank." Zhurnal Nevrologii i Psikhiatrii.
3. Kolomin T, Shadrina M, Slominsky P, Limborska S, Myasoedov N. "A study of the transcriptional effects of Selank in the rat brain." Journal of Molecular Neuroscience.
4. Vyunova TV, et al. "Peptide regulation of specific ligand-receptor interactions: Selank and tuftsin." Russian Journal of Bioorganic Chemistry.

References are provided for background reading and do not constitute endorsement of any use.

The Peptide Review publishes educational summaries of the scientific literature. Nothing here is medical advice, and nothing here describes a use for any product. Compounds discussed are reference materials for qualified in-vitro laboratory research only and are not drugs, supplements, or products for human or animal consumption.